Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model.

Chanho KongEun-Jeong YangJaewoo ShinJunwon ParkSi-Hyun KimSeong-Wook ParkWon Seok ChangChang-Han LeeHyunju KimHye-Sun Kim Jin Woo Chang

Published in: Translational neurodegeneration (2022)

In conclusion, the enhanced delivery of a low dose of Adu (3 mg/kg) via FUS decreases amyloid deposits and attenuates cognitive function deficits. FUS-mediated BBB opening increases adult hippocampal neurogenesis as well as drug delivery. We present an AD treatment strategy through the synergistic effect of the combined therapy of FUS and Adu.

Keyphrases

low dose
drug delivery
high dose
cancer therapy
blood brain barrier
traumatic brain injury
cerebral ischemia
high fat diet induced
metabolic syndrome
adipose tissue
bone marrow
brain injury